FDA 483 - SRI Krishna Pharmaceuticals Ltd - Unit I - April 18, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Sri Krishna Pharmaceuticals Limited Unit I in Hyderabad, Telangana, was cited for significant deficiencies across its API manufacturing operations. The inspection revealed widespread issues with facility and equipment maintenance, inadequate contamination control during product handling, and a systemic failure in conducting comprehensive investigations into quality events and implementing effective corrective and preventive actions. Additionally, the quality control unit demonstrated deficient oversight of laboratory electronic systems and data integrity, and cleaning procedures were found to be inadequate.
ID · acb7723a-121f-4a23-a724-9e6969aa8323